---
title: "iSpecimen (ISPC.US) Surges 18% on Reverse Split"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284914849.md"
description: "iSpecimen（ISPC.US）现价 $6.190，当日 +18.36%，5 分钟涨幅超过 3%，市值 0.05 亿。公司主营生命科学样本解决方案。股价异动主要因宣布 1 比 40 反向拆股，市场对拆股后股本结构变化表现关注。目前暂无其他公开重大消息。"
datetime: "2026-05-01T15:21:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284914849.md)
  - [en](https://longbridge.com/en/news/284914849.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284914849.md)
---

# iSpecimen (ISPC.US) Surges 18% on Reverse Split

iSpecimen (ISPC.US) is trading at $6.190, up **18.36%** intraday with a 5-minute gain exceeding 3%, market cap at $5 million.

The company focuses on life science specimen solutions. The strong price movement was triggered by news of a 1-for-40 reverse stock split, drawing attention to post-split share structure. No other major catalysts have been disclosed.

### Related Stocks

- [ISPC.US](https://longbridge.com/en/quote/ISPC.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)
- [ISpecimen Announces Private Placement Worth $2.5 Mln](https://longbridge.com/en/news/285937495.md)
- [iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement | ISPC Stock News](https://longbridge.com/en/news/285787160.md)
- [Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2](https://longbridge.com/en/news/287200923.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)